Cardiac alpha1-adrenergic receptors: Novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance

Pharmacological Reviews

Volumn 66, Issue 1, 2014, Pages 308-333

  O'Connell, Timothy D ^a   Jensen, Brian C ^b   Baker, Anthony J ^c   Simpson, Paul C ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CARVEDILOL; G PROTEIN COUPLED RECEPTOR; NORADRENALIN;

ADAPTIVE HYPERTROPHY; ANTIHYPERTENSIVE THERAPY; ARTICLE; CATECHOLAMINE UPTAKE; CELL CULTURE; CELL DEATH; CELL NUCLEUS MEMBRANE; CLINICAL TRIAL (TOPIC); EXPERIMENTAL MODEL; GENE DELETION; HEART; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; HYPERTENSION; HYPERTROPHY; IN VITRO STUDY; ISCHEMIC PRECONDITIONING; MUSCLE CONTRACTILITY; NONHUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; RISK; SURVIVAL; ANIMAL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HEART; HEART DISEASES; HUMANS; MYOCYTES, CARDIAC; RECEPTORS, ADRENERGIC, ALPHA-1; SIGNAL TRANSDUCTION;

EID: 84891609139     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.112.007203     Document Type: Article

References (327)

1. Adams JW and Brown JH (2001) G-proteins in growth and apoptosis: lessons from the heart. Oncogene 20:1626-1634.
2. q signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci USA 95: 10140-10145.
3. Agüero J, Almenar L, Montó F, Oliver E, Sánchez-Lázaro I, Vicente D, Martínez-Dolz L, D'Ocon P, Rueda J, and Salvador A (2012) Myocardial G protein receptorcoupled kinase expression correlates with functional parameters and clinical severity in advanced heart failure. J Card Fail 18:53-61.
4. Ainscough JF, Drinkhill MJ, Sedo A, Turner NA, Brooke DA, Balmforth AJ, and Ball SG (2009) Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction. Cardiovasc Res 81: 592-600.
5. Akhter SA, Milano CA, Shotwell KF, Cho MC, Rockman HA, Lefkowitz RJ, and Koch WJ (1997) Transgenic mice with cardiac overexpression of alpha1B-adrenergic receptors. In vivo alpha1-adrenergic receptor-mediated regulation of betaadrenergic signaling. J Biol Chem 272:21253-21259.
6. ALLHAT Collaborative Research Group (2000) Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) [published correction appears in JAMA (2002) 288:2976]. JAMA 283:1967-1975.
7. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group (2003) Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 42:239-246.
8. Amirahmadi F, Turnbull L, Du XJ, Graham RM, and Woodcock EA (2008) Heightened alpha1A-adrenergic receptor activity suppresses ischaemia/reperfusion-induced Ins (1,4,5)P3 generation in the mouse heart: a comparison with ischaemic preconditioning. Clin Sci (Lond) 114:157-164.
9. Anand IS and Florea VG (2003) Alterations in ventricular structure: Role of left ventricular remodeling, in Heart Failure: A Companion to Braunwald's Heart Disease (Mann DL, ed) pp 229-245, WB Saunders Co.
10. Andersen GO, Qvigstad E, Schiander I, Aass H, Osnes JB, and Skomedal T (2002) Alpha(1)-AR-induced positive inotropic response in heart is dependent on myosin light chain phosphorylation. Am J Physiol Heart Circ Physiol 283:H1471-H1480.
11. Apkon M and Nerbonne JM (1988) Alpha 1-adrenergic agonists selectively suppress voltage-dependent K+ current in rat ventricular myocytes. Proc Natl Acad Sci USA 85:8756-8760.
12. Aries A, Paradis P, Lefebvre C, Schwartz RJ, and Nemer M (2004) Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci USA 101:6975-6980.
13. Autelitano DJ and Woodcock EA (1998) Selective activation of alpha1A-adrenergic receptors in neonatal cardiac myocytes is sufficient to cause hypertrophy and differential regulation of alpha1-adrenergic receptor subtype mRNAs. J Mol Cell Cardiol 30:1515-1523.
14. Avkiran M, Rowland AJ, Cuello F, and Haworth RS (2008) Protein kinase d in the cardiovascular system: emerging roles in health and disease. Circ Res 102: 157-163.
15. Backs J, Backs T, Bezprozvannaya S, McKinsey TA, and Olson EN (2008) Histone deacetylase 5 acquires calcium/calmodulin-dependent kinase II responsiveness by oligomerization with histone deacetylase 4. Mol Cell Biol 28:3437-3445.
16. Backs J, Song K, Bezprozvannaya S, Chang S, and Olson EN (2006) CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J Clin Invest 116:1853-1864.
17. Baghelai K, Graham LJ, Wechsler AS, and Jakoi ER (1999a) Delayed myocardial preconditioning by alpha1-adrenoceptors involves inhibition of apoptosis. J Thorac Cardiovasc Surg 117:980-986.
18. Baghelai K, Graham LJ, Wechsler AS, and Jakoi ER (1999b) Phenylephrine induces delayed cardioprotection against necrosis without amelioration of stunning. Ann Thorac Surg 68:1219-1224.
19. Baines CP (2010) Role of the mitochondrion in programmed necrosis. Front Physiol 1: 156.
20. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, Brunskill EW, Sayen MR, Gottlieb RA, and Dorn GW, et al. (2005) Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434:658-662.
21. Banerjee A, Locke-Winter C, Rogers KB, Mitchell MB, Brew EC, Cairns CB, Bensard DD, and Harken AH (1993) Preconditioning against myocardial dysfunction after ischemia and reperfusion by an alpha 1-adrenergic mechanism. Circ Res 73: 656-670.
22. Bankwala Z, Hale SL, and Kloner RA (1994) Alpha-adrenoceptor stimulation with exogenous norepinephrine or release of endogenous catecholamines mimics ischemic preconditioning. Circulation 90:1023-1028.
23. Barron AJ, Finn SG, and Fuller SJ (2003) Chronic activation of extracellular-signalregulated protein kinases by phenylephrine is required to elicit a hypertrophic response in cardiac myocytes. Biochem J 371:71-79.
24. Belevych AE, Nulton-Persson A, Sims C, and Harvey RD (2001) Role of tyrosine kinase activity in alpha-adrenergic inhibition of the beta-adrenergically regulated L-type Ca(2+) current in guinea-pig ventricular myocytes. J Physiol 537:779-792.
25. Bishopric NH, Simpson PC, and Ordahl CP (1987) Induction of the skeletal alphaactin gene in alpha 1-adrenoceptor-mediated hypertrophy of rat cardiac myocytes. J Clin Invest 80:1194-1199.
26. Bkaily G, Avedanian L, and Jacques D (2009) Nuclear membrane receptors and channels as targets for drug development in cardiovascular diseases. Can J Physiol Pharmacol 87:108-119.
27. Bleasdale RA and Frenneaux MP (2002) Prognostic importance of right ventricular dysfunction. Heart 88:323-324.
28. Böhm M, Diet F, Feiler G, Kemkes B, and Erdmann E (1988) Alpha-adrenoceptors and alpha-adrenoceptor-mediated positive inotropic effects in failing human myocardium. J Cardiovasc Pharmacol 12:357-364.
29. Boivin B, Chevalier D, Villeneuve LR, Rousseau E, and Allen BG (2003) Functional endothelin receptors are present on nuclei in cardiac ventricular myocytes. J Biol Chem 278:29153-29163.
30. Boivin B, Lavoie C, Vaniotis G, Baragli A, Villeneuve LR, Ethier N, Trieu P, Allen BG, and Hébert TE (2006) Functional beta-adrenergic receptor signalling on nuclear membranes in adult rat and mouse ventricular cardiomyocytes. Cardiovasc Res 71:69-78.
31. Boivin B, Vaniotis G, Allen BG, and Hébert TE (2008) G protein-coupled receptors in and on the cell nucleus: a new signaling paradigm? J Recept Signal Transduct Res 28:15-28.
32. Bossuyt J, Chang CW, Helmstadter K, Kunkel MT, Newton AC, Campbell KS, Martin JL, Bossuyt S, Robia SL, and Bers DM (2011) Spatiotemporally distinct protein kinase D activation in adult cardiomyocytes in response to phenylephrine and endothelin. J Biol Chem 286:33390-33400.
33. 2+/calmodulin-dependent protein kinase IIdelta and protein kinase D overexpression reinforce the histone deacetylase 5 redistribution in heart failure. Circ Res 102:695-702.
34. Brahmadevara N, Shaw AM, and MacDonald A (2003) Evidence against beta 3-adrenoceptors or low affinity state of beta 1-adrenoceptors mediating relaxation in rat isolated aorta. Br J Pharmacol 138:99-106.
35. Brahmadevara N, Shaw AM, and MacDonald A (2004) Alpha1-adrenoceptor antagonist properties of CGP 12177A and other beta-adrenoceptor ligands: evidence against beta(3)-or atypical beta-adrenoceptors in rat aorta. Br J Pharmacol 142: 781-787.
36. Braun AP, Fedida D, and Giles WR (1992) Activation of alpha 1-adrenoceptors modulates the inwardly rectifying potassium currents of mammalian atrial myocytes. Pflugers Arch 421:431-439.
37. Braz JC, Bueno OF, De Windt LJ, and Molkentin JD (2002) PKC alpha regulates the hypertrophic growth of cardiomyocytes through extracellular signal-regulated kinase1/2 (ERK1/2). J Cell Biol 156:905-919.
38. Braz JC, Gregory K, Pathak A, Zhao W, Sahin B, Klevitsky R, Kimball TF, Lorenz JN, Nairn AC, and Liggett SB, et al. (2004) PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 10:248-254.
39. Bristow MR (2000) beta-adrenergic receptor blockade in chronic heart failure. Circulation 101:558-569.
40. Bristow MR, Feldman AM, Adams KF Jr, and Goldstein S (2003) Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? J Card Fail 9:444-453.
41. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, and Stinson EB (1982) Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 307:205-211.
42. Bristow MR, Krause-Steinrauf H, Nuzzo R, Liang CS, Lindenfeld J, Lowes BD, Hattler B, Abraham WT, Olson L, and Krueger S, et al. (2004) Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation 110:1437-1442.
43. Bristow MR, Minobe W, Rasmussen R, Hershberger RE, and Hoffman BB (1988) Alpha-1 adrenergic receptors in the nonfailing and failing human heart. J Pharmacol Exp Ther 247:1039-1045.
44. Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, Hewett TE, Jones SP, Lefer DJ, and Peng CF, et al. (2000) The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenicmice. EMBO J 19:6341-6350.
45. Buu NT, Hui R, and Falardeau P (1993) Norepinephrine in neonatal rat ventricular myocytes: association with the cell nucleus and binding to nuclear alpha 1-and beta-adrenergic receptors. J Mol Cell Cardiol 25:1037-1046.
46. Cabanes L, Costes F, Weber S, Regnard J, Benvenuti C, Castaigne A, Guerin F, and Lockhart A (1992) Improvement in exercise performance by inhalation of methoxamine in patients with impaired left ventricular function. N Engl J Med 326:1661-1665.
47. Caine M, Perlberg S, and Meretyk S (1978) A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 50:551-554.
48. Caine M, Pfau A, and Perlberg S (1976) The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 48:255-263.
49. Carnegie GK, Soughayer J, Smith FD, Pedroja BS, Zhang F, Diviani D, Bristow MR, Kunkel MT, Newton AC, and Langeberg LK, et al. (2008) AKAP-Lbc mobilizes a cardiac hypertrophy signaling pathway. Mol Cell 32:169-179.
50. Cavalli A, Lattion AL, Hummler E, Nenniger M, Pedrazzini T, Aubert JF, Michel MC, Yang M, Lembo G, and Vecchione C, et al. (1997) Decreased blood pressure response in mice deficient of the alpha1b-adrenergic receptor. Proc Natl Acad Sci USA 94:11589-11594.
51. Chalothorn D, McCune DF, Edelmann SE, García-Cazarín ML, Tsujimoto G, and Piascik MT (2002) Differences in the cellular localization and agonist-mediated internalization properties of the alpha(1)-adrenoceptor subtypes. Mol Pharmacol 61:1008-1016.
52. Chalothorn D, McCune DF, Edelmann SE, Tobita K, Keller BB, Lasley RD, Perez DM, Tanoue A, Tsujimoto G, and Post GR, et al. (2003) Differential cardiovascular regulatory activities of the alpha 1B-and alpha 1D-adrenoceptor subtypes. J Pharmacol Exp Ther 305:1045-1053.
53. Chan T, Dash R, and Simpson PC (2008) An alpha-1A-adrenergic receptor subtype agonist prevents cardiomyopathy without increasing blood pressure. abstract Circulation 118:S533.
54. Chatterjee S, Biondi-Zoccai G, Abbate A, D'Ascenzo F, Castagno D, Van Tassell B, Mukherjee D, and Lichstein E (2013) Benefits of βblockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ 346:f55.
55. Chaulet H, Lin F, Guo J, Owens WA, Michalicek J, Kesteven SH, Guan Z, Prall OW, Mearns BM, and Feneley MP, et al. (2006) Sustained augmentation of cardiac alpha1A-adrenergic drive results in pathological remodeling with contractile dysfunction, progressive fibrosis and reactivation of matricellular protein genes. J Mol Cell Cardiol 40:540-552.
56. Chen HH, Mullett SJ, and Stewart AF (2004) Vgl-4, a novel member of the vestigiallike family of transcription cofactors, regulates alpha1-adrenergic activation of gene expression in cardiac myocytes. J Biol Chem 279:30800-30806.
57. 2+ currents in cardiac ventricular myocytes. Circ Res 79:184-193.
58. Chen R, Mukhin YV, Garnovskaya MN, Thielen TE, Iijima Y, Huang C, Raymond JR, Ullian ME, and Paul RV (2000) A functional angiotensin II receptor-GFP fusion protein: evidence for agonist-dependent nuclear translocation. Am J Physiol Renal Physiol 279:F440-F448.
59. Chrysant SG (2008) Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum. Clin Ther 30:2181-2190.
60. Chu C, Thai K, Park KW, Wang P, Makwana O, Lovett DH, Simpson PC, and Baker AJ (2013) Intraventricular and interventricular cellular heterogeneity of inotropic responses to α(1)-adrenergic stimulation. Am J Physiol Heart Circ Physiol 304: H946-H953.
61. CIBIS-II (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353:9-13.
62. Clark WA, Rudnick SJ, LaPres JJ, Andersen LC, and LaPointe MC (1993) Regulation of hypertrophy and atrophy in cultured adult heart cells. Circ Res 73:1163-1176.
63. Cleveland JC Jr, Meldrum DR, Rowland RT, Cain BS, Meng X, Gamboni-Robertson F, Banerjee A, and Harken AH (1997) Ischemic preconditioning of human myocardium: protein kinase C mediates a permissive role for alpha 1-adrenoceptors. Am J Physiol 273:H902-H908.
64. Cleveland JC Jr, Wollmering MM, Meldrum DR, Rowland RT, Rehring TF, Sheridan BC, Harken AH, and Banerjee A (1996) Ischemic preconditioning in human and rat ventricle. Am J Physiol 271:H1786-H1794.
65. Coats AJ (1999) Heart Failure 99-the MOXCON story. Int J Cardiol 71:109-111.
66. Cohn JN (1993) The Vasodilator-Heart Failure Trials (V-HeFT). Mechanistic data from the VA Cooperative Studies. Introduction. Circulation 87(6, Suppl)VI1-VI4.
67. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, and Flohr KH, et al. (1986) Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 314:1547-1552.
68. Cohn JN and Franciosa JA (1977a) Vasodilator therapy of cardiac failure (second of two parts). N Engl J Med 297:254-258.
69. Cohn JN and Franciosa JA (1977b) Vasodilator therapy of cardiac failure: (first of two parts). N Engl J Med 297:27-31.
70. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, and Rector T (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819-823.
71. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, and Wright TJ; MOXCON Investigators (2003) Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 5:659-667.
72. Communal C, Singh K, Pimentel DR, and Colucci WS (1998) Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the betaadrenergic pathway. Circulation 98:1329-1334.
73. Communal C, Singh M, Menon B, Xie Z, Colucci WS, and Singh K (2003) beta1 integrins expression in adult rat ventricular myocytes and its role in the regulation of beta-adrenergic receptor-stimulated apoptosis. J Cell Biochem 89:381-388.
74. Cook A, Bono F, Jinek M, and Conti E (2007) Structural biology of nucleocytoplasmic transport. Annu Rev Biochem 76:647-671.
75. Cope JT, Mauney MC, Banks D, Binns OA, Moore CL, Rentz JJ, Shockey KS, King RC, Kron IL, and Tribble CG (1997) Intravenous phenylephrine preconditioning of cardiac grafts from non-heart-beating donors. Ann Thorac Surg 63:1664-1668.
76. Cotecchia S (2010) The α1-adrenergic receptors: diversity of signaling networks and regulation. J Recept Signal Transduct Res 30:410-419.
77. Curiel R, Pérez-González J, Brito N, Zerpa R, Téllez D, Cabrera J, Curiel C, and Cubeddu L (1989) Positive inotropic effects mediated by alpha 1 adrenoceptors in intact human subjects. J Cardiovasc Pharmacol 14:603-615.
78. Daly CJ, Milligan CM, Milligan G, Mackenzie JF, and Mcgrath JC (1998) Cellular localization and pharmacological characterization of functioning alpha-1 adrenoceptors by fluorescent ligand binding and image analysis reveals identical binding properties of clustered and diffuse populations of receptors. J Pharmacol Exp Ther 286:984-990.
79. Dash R, Chung J, Chan T, Yamada M, Barral J, Nishimura D, Yang PC, and Simpson PC (2011) A molecular MRI probe to detect treatment of cardiac apoptosis in vivo. Magn Reson Med 66:1152-1162.
80. Davis BR, Cutler JA, Furberg CD, Wright JT, Farber MA, Felicetta JV, and Stokes JD; ALLHAT Collaborative Research Group (2002) Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Ann Intern Med 137:313-320.
81. Debrus S, Rahbani L, Marttila M, Delorme B, Paradis P, and Nemer M (2005) The zinc finger-only protein Zfp260 is a novel cardiac regulator and a nuclear effector of alpha1-adrenergic signaling. Mol Cell Biol 25:8669-8682.
82. Dhaliwal AS, Habib G, Deswal A, Verduzco M, Souchek J, Ramasubbu K, Aguilar D, Ma TS, Jneid HM, and Bolos M, et al. (2009) Impact of alpha 1-adrenergic antagonist use for benign prostatic hypertrophy on outcomes in patients with heart failure. Am J Cardiol 104:270-275.
83. Dono R, James D, and Zeller R (1998) A GR-motif functions in nuclear accumulation of the large FGF-2 isoforms and interferes with mitogenic signalling. Oncogene 16: 2151-2158.
84. Dorn GW 2nd (2005) Physiologic growth and pathologic genes in cardiac development and cardiomyopathy. Trends Cardiovasc Med 15:185-189.
85. Dorn GW 2nd and Brown JH (1999) Gq signaling in cardiac adaptation and maladaptation. Trends Cardiovasc Med 9:26-34.
86. Drake MT, Shenoy SK, and Lefkowitz RJ (2006) Trafficking of G protein-coupled receptors. Circ Res 99:570-582.
87. Du XJ, Fang L, Gao XM, Kiriazis H, Feng X, Hotchkin E, Finch AM, Chaulet H, and Graham RM (2004) Genetic enhancement of ventricular contractility protects against pressure-overload-induced cardiac dysfunction. J Mol Cell Cardiol 37: 979-987.
88. Du XJ, Gao XM, Kiriazis H, Moore XL, Ming Z, Su Y, Finch AM, Hannan RA, Dart AM, and Graham RM (2006) Transgenic alpha1A-adrenergic activation limits postinfarct ventricular remodeling and dysfunction and improves survival. Cardiovasc Res 71:735-743.
89. Duan H and Wang J (2010) Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther 335:743-753.
90. Eckhart AD, Duncan SJ, Penn RB, Benovic JL, Lefkowitz RJ, and Koch WJ (2000) Hybrid transgenic mice reveal in vivo specificity of G protein-coupled receptor kinases in the heart. Circ Res 86:43-50.
91. 2+ mediated through alpha-and beta-adrenoceptors. Circ Res 62:247-265.
92. Fawzy A, Vashi V, Chung M, Dias N, and Gaffney M; Multicenter Study Group (1999) Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Urology 53:329-335.
93. Fedida D, Braun AP, and Giles WR (1991) Alpha 1-adrenoceptors reduce background K+ current in rabbit ventricular myocytes. J Physiol 441:673-684.
94. Fedida D, Shimoni Y, and Giles WR (1989) A novel effect of norepinephrine on cardiac cells is mediated by alpha 1-adrenoceptors. Am J Physiol 256:H1500-H1504.
95. Fedida D, Shimoni Y, and Giles WR (1990) Alpha-adrenergic modulation of the transient outward current in rabbit atrial myocytes. J Physiol 423:257-277.
96. Filipeanu CM, Zhou F, Fugetta EK, and Wu G (2006) Differential regulation of the cell-surface targeting and function of beta-and alpha1-adrenergic receptors by Rab1 GTPase in cardiac myocytes. Mol Pharmacol 69:1571-1578.
97. Filtz TM, Grubb DR, McLeod-Dryden TJ, Luo J, and Woodcock EA (2009) Gqinitiated cardiomyocyte hypertrophy is mediated by phospholipase Cbeta1b. FASEB J 23:3564-3570.
98. Foo RS, Mani K, and Kitsis RN (2005) Death begets failure in the heart. J Clin Invest 115:565-571.
99. Foody JM, Farrell MH, and Krumholz HM (2002) beta-Blocker therapy in heart failure: scientific review. JAMA 287:883-889.
100. Frey N and Olson EN (2003) Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65:45-79.
101. Frishman WH and Kotob F (1999) Alpha-adrenergic blocking drugs in clinical medicine. J Clin Pharmacol 39:7-16.
102. Fujita T, Toya Y, Iwatsubo K, Onda T, Kimura K, Umemura S, and Ishikawa Y (2001) Accumulation of molecules involved in alpha1-adrenergic signal within caveolae: caveolin expression and the development of cardiac hypertrophy. Cardiovasc Res 51:709-716.
103. Fuller SJ, Gaitanaki CJ, and Sugden PH (1990) Effects of catecholamines on protein synthesis in cardiac myocytes and perfused hearts isolated from adult rats. Stimulation of translation is mediated through the alpha 1-adrenoceptor. Biochem J 266:727-736.
104. 2+ in cardiac myocytes. Circ Res 71:870-882.
105. 2+ and pH homeostasis in rat cardiac myocytes. Am J Physiol 274:H1152-H1162.
106. Gao XM, Wang BH, Woodcock E, and Du XJ (2000) Expression of active alpha(1B)-adrenergic receptors in the heart does not alleviate ischemic reperfusion injury. J Mol Cell Cardiol 32:1679-1686.
107. Gaughan JP, Hefner CA, and Houser SR (1998) Electrophysiological properties of neonatal rat ventricular myocytes with alpha1-adrenergic-induced hypertrophy. Am J Physiol 275:H577-H590.
108. Glembotski CC (2013) Classic studies of cultured cardiac myocyte hypertrophy: interview with a transformer. Circ Res 113:1112-1116.
109. Gobeil F Jr, Dumont I, Marrache AM, Vazquez-Tello A, Bernier SG, Abran D, Hou X, Beauchamp MH, Quiniou C, and Bouayad A, et al. (2002) Regulation of eNOS expression in brain endothelial cells by perinuclear EP(3) receptors. Circ Res 90:682-689.
110. Gobeil F, Fortier A, Zhu T, Bossolasco M, Leduc M, Grandbois M, Heveker N, Bkaily G, Chemtob S, and Barbaz D (2006) G-protein-coupled receptors signalling at the cell nucleus: an emerging paradigm. Can J Physiol Pharmacol 84:287-297.
111. González-Juanatey JR, Iglesias MJ, Alcaide C, Piñeiro R, and Lago F (2003) Doxazosin induces apoptosis in cardiomyocytes cultured in vitro by a mechanism that is independent of alpha1-adrenergic blockade. Circulation 107:127-131.
112. Graham RM, Perez DM, Hwa J, and Piascik MT (1996) Alpha 1-adrenergic receptor subtypes. Molecular structure, function, and signaling. Circ Res 78:737-749.
113. Gray MO, Long CS, Kalinyak JE, Li HT, and Karliner JS (1998) Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc Res 40:352-363.
114. Grubb DR, Vasilevski O, Huynh H, and Woodcock EA (2008) The extreme C-terminal region of phospholipase Cbeta1 determines subcellular localization and function; the "b" splice variant mediates alpha1-adrenergic receptor responses in cardiomyocytes. FASEB J 22:2768-2774.
115. Grupp IL, Lorenz JN, Walsh RA, Boivin GP, and Rindt H (1998) Overexpression of alpha1B-adrenergic receptor induces left ventricular dysfunction in the absence of hypertrophy. Am J Physiol 275:H1338-H1350.
116. Guerra S, Leri A, Wang X, Finato N, Di Loreto C, Beltrami CA, Kajstura J, and Anversa P (1999) Myocyte death in the failing human heart is gender dependent. Circ Res 85:856-866.
117. Guo J, Gertsberg Z, Ozgen N, and Steinberg SF (2009) p66Shc links alpha1-adrenergic receptors to a reactive oxygen species-dependent AKT-FOXO3A phosphorylation pathway in cardiomyocytes. Circ Res 104:660-669.
118. Harada K, Sugaya T, Murakami K, Yazaki Y, and Komuro I (1999) Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. see comments Circulation 100: 2093-2099.
119. Harrison BC, Kim MS, van Rooij E, Plato CF, Papst PJ, Vega RB, McAnally JA, Richardson JA, Bassel-Duby R, and Olson EN, et al. (2006) Regulation of cardiac stress signaling by protein kinase d1. Mol Cell Biol 26:3875-3888.
120. Hartmann M, Stumpe T, and Schrader J (1995) alpha 1-Adrenoceptor stimulation inhibits the isoproterenol-induced effects on myocardial contractility and protein phosphorylation. Eur J Pharmacol 287:57-64.
121. Haworth RS, Goss MW, Rozengurt E, and Avkiran M (2000) Expression and activity of protein kinase D/protein kinase C mu in myocardium: evidence for alpha1-adrenergic receptor-and protein kinase C-mediated regulation. J Mol Cell Cardiol 32:1013-1023.
122. Hein P and Michel MC (2007) Signal transduction and regulation: are all alpha1-adrenergic receptor subtypes created equal? Biochem Pharmacol 73:1097-1106.
123. Hennenberg M, Schlenker B, Roosen A, Strittmatter F, Walther S, Stief C, and Gratzke C (2011) β-arrestin-2 is expressed in human prostate smooth muscle and a binding partner of α1A-adrenoceptors. World J Urol 29:157-163.
124. Henrich CJ and Simpson PC (1988) Differential acute and chronic response of protein kinase C in cultured neonatal rat heart myocytes to alpha 1-adrenergic and phorbol ester stimulation. J Mol Cell Cardiol 20:1081-1085.
125. Hirano S, Kusakari Y, O-Uchi J, Morimoto S, Kawai M, Hongo K, and Kurihara S (2006) Intracellular mechanism of the negative inotropic effect induced by alpha1-adrenoceptor stimulation in mouse myocardium. J Physiol Sci 56:297-304.
126. Hock R, Scheer U, and Bustin M (1998) Chromosomal proteins HMG-14 and HMG-17 are released from mitotic chromosomes and imported into the nucleus by active transport. J Cell Biol 143:1427-1436.
127. Hosoda C, Koshimizu TA, Tanoue A, Nasa Y, Oikawa R, Tomabechi T, Fukuda S, Shinoura H, Oshikawa S, and Takeo S, et al. (2005) Two alpha1-adrenergic receptor subtypes regulating the vasopressor response have differential roles in blood pressure regulation. Mol Pharmacol 67:912-922.
128. Hryniewicz K, Androne AS, Hudaihed A, and Katz SD (2003) Comparative effects of carvedilol and metoprolol on regional vascular responses to adrenergic stimuli in normal subjects and patients with chronic heart failure. Circulation 108:971-976.
129. Hu K and Nattel S (1995) Mechanisms of ischemic preconditioning in rat hearts. Involvement of alpha 1B-adrenoceptors, pertussis toxin-sensitive G proteins, and protein kinase C. Circulation 92:2259-2265.
130. Huang Y, Wright CD, Kobayashi S, Healy CL, Elgethun M, Cypher A, Liang Q, and O'Connell TD (2008) GATA4 is a survival factor in adult cardiac myocytes but is not required for {alpha}1A-adrenergic receptor survival signaling. Am J Physiol 295:H699-H707.
131. Huang Y, Wright CD, Merkwan CL, Baye NL, Liang Q, Simpson PC, and O'Connell TD (2007) An alpha1A-adrenergic-extracellular signal-regulated kinase survival signaling pathway in cardiac myocytes. Circulation 115:763-772.
132. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, and Michl K, et al.; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112: e154-e235.
133. Hwang KC, Gray CD, Sweet WE, Moravec CS, and Im MJ (1996) Alpha 1-adrenergic receptor coupling with Gh in the failing human heart. Circulation 94:718-726.
134. Iaccarino G, Keys JR, Rapacciuolo A, Shotwell KF, Lefkowitz RJ, Rockman HA, and Koch WJ (2001) Regulation of myocardial betaARK1 expression in catecholamine-induced cardiac hypertrophy in transgenic mice overexpressing alpha1B-adrenergic receptors. J Am Coll Cardiol 38:534-540.
135. Ichishima K, Yamamoto S, Iwamoto T, and Ehara T (2010) alpha-Adrenoceptormediated depletion of phosphatidylinositol 4, 5-bisphosphate inhibits activation of volume-regulated anion channels in mouse ventricular myocytes. Br J Pharmacol 161:193-206.
136. Ikeda U, Tsuruya Y, and Yaginuma T (1991) Alpha 1-adrenergic stimulation is coupled to cardiac myocyte hypertrophy. Am J Physiol 260:H953-H956.
137. Imani A, Faghihi M, Sadr SS, Keshavarz M, and Niaraki SS (2008) Noradrenaline reduces ischemia-induced arrhythmia in anesthetized rats: involvement of alpha1-adrenoceptors and mitochondrial K ATP channels. J Cardiovasc Electrophysiol 19: 309-315.
138. Iwai-Kanai E, Hasegawa K, Araki M, Kakita T, Morimoto T, and Sasayama S (1999) alpha-and beta-adrenergic pathways differentially regulate cell type-specific apoptosis in rat cardiac myocytes. Circulation 100:305-311.
139. Jensen BC, O'Connell TD, and Simpson PC (2011) Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure. J Mol Cell Cardiol 51:518-528.
140. Jensen BC, Swigart PM, De Marco T, Hoopes C, and Simpson PC (2009a) alpha1-Adrenergic receptor subtypes in nonfailing and failing human myocardium. Circ Heart Fail 2:654-663.
141. Jensen BC, Swigart PM, Laden ME, DeMarco T, Hoopes C, and Simpson PC (2009b) The alpha-1D Is the predominant alpha-1-adrenergic receptor subtype in human epicardial coronary arteries. J Am Coll Cardiol 54:1137-1145.
142. Jensen BC, Swigart PM, Montgomery MD, and Simpson PC (2010) Functional alpha-1B adrenergic receptors on human epicardial coronary artery endothelial cells. Naunyn Schmiedebergs Arch Pharmacol 382:475-482.
143. Jensen BC, Swigart PM, and Simpson PC (2009c) Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific. Naunyn Schmiedebergs Arch Pharmacol 379:409-412.
144. Jin Y, Sheikh F, Detillieux KA, and Cattini PA (2000) Role for early growth response-1 protein in alpha(1)-adrenergic stimulation of fibroblast growth factor-2 promoter activity in cardiac myocytes. Mol Pharmacol 57:984-990.
145. Kariya K, Farrance IK, and Simpson PC (1993) Transcriptional enhancer factor-1 in cardiac myocytes interacts with an alpha 1-adrenergic-and beta-protein kinase C-inducible element in the rat beta-myosin heavy chain promoter. J Biol Chem 268:26658-26662.
146. Kariya K, Karns LR, and Simpson PC (1991) Expression of a constitutively activated mutant of the beta-isozyme of protein kinase C in cardiac myocytes stimulates the promoter of the beta-myosin heavy chain isogene. J Biol Chem 266: 10023-10026.
147. Kariya K, Karns LR, and Simpson PC (1994) An enhancer core element mediates stimulation of the rat beta-myosin heavy chain promoter by an alpha 1-adrenergic agonist and activated beta-protein kinase C in hypertrophy of cardiac myocytes. J Biol Chem 269:3775-3782.
148. Karns LR, Kariya K, and Simpson PC (1995) M-CAT, CArG, and Sp1 elements are required for alpha 1-adrenergic induction of the skeletal alpha-actin promoter during cardiac myocyte hypertrophy. Transcriptional enhancer factor-1 and protein kinase C as conserved transducers of the fetal program in cardiac growth. J Biol Chem 270:410-417.
149. Kim NN, Villarreal FJ, Printz MP, Lee AA, and Dillmann WH (1995) Trophic effects of angiotensin II on neonatal rat cardiac myocytes are mediated by cardiac fibroblasts. Am J Physiol 269:E426-E437.
150. King BD, Sack D, Kichuk MR, and Hintze TH (1987) Absence of hypertension despite chronic marked elevations in plasma norepinephrine in conscious dogs. Hypertension 9:582-590.
151. King MC, Lusk CP, and Blobel G (2006) Karyopherin-mediated import of integral inner nuclear membrane proteins. Nature 442:1003-1007.
152. Kitakaze M, Hori M, Morioka T, Minamino T, Takashima S, Sato H, Shinozaki Y, Chujo M, Mori H, and Inoue M, et al. (1994) Alpha 1-adrenoceptor activation mediates the infarct size-limiting effect of ischemic preconditioning through augmentation of 5'-nucleotidase activity. J Clin Invest 93:2197-2205.
153. Kitakaze M, Hori M, Sato H, Iwakura K, Gotoh K, Inoue M, Kitabatake A, and Kamada T (1991) Beneficial effects of alpha 1-adrenoceptor activity on myocardial stunning in dogs. Circ Res 68:1322-1339.
154. Kitakaze M, Hori M, Tamai J, Iwakura K, Koretsune Y, Kagiya T, Iwai K, Kitabatake A, Inoue M, and Kamada T (1987) Alpha 1-adrenoceptor activity regulates release of adenosine from the ischemic myocardium in dogs. Circ Res 60:631-639.
155. Knowlton KU, Baracchini E, Ross RS, Harris AN, Henderson SA, Evans SM, Glembotski CC, and Chien KR (1991) Co-regulation of the atrial natriuretic factor and cardiac myosin light chain-2 genes during alpha-adrenergic stimulation of neonatal rat ventricular cells. Identification of cis sequences within an embryonic and a constitutive contractile protein gene which mediate inducible expression. J Biol Chem 266:7759-7768.
156. Knowlton KU, Michel MC, Itani M, Shubeita HE, Ishihara K, Brown JH, and Chien KR (1993) The alpha 1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. J Biol Chem 268:15374-15380.
157. Koshimizu TA, Tsujimoto G, Hirasawa A, Kitagawa Y, and Tanoue A (2004) Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D-and alpha1B-adrenergic receptors. Cardiovasc Res 63:662-672.
158. Kostin S, Pool L, Elsässer A, Hein S, Drexler HC, Arnon E, Hayakawa Y, Zimmermann R, Bauer E, and Klövekorn WP, et al. (2003) Myocytes die by multiple mechanisms in failing human hearts. Circ Res 92:715-724.
159. Kubo T, Azevedo ER, Newton GE, Parker JD, and Floras JS (2001) Lack of evidence for peripheral alpha(1)-adrenoceptor blockade during long-term treatment of heart failure with carvedilol. J Am Coll Cardiol 38:1463-1469.
160. Laks MM, Morady F, and Swan HJ (1973) Myocardial hypertrophy produced by chronic infusion of subhypertensive doses of norepinephrine in the dog. Chest 64: 75-78.
161. Landzberg JS, Parker JD, Gauthier DF, and Colucci WS (1991) Effects of myocardial alpha 1-adrenergic receptor stimulation and blockade on contractility in humans. Circulation 84:1608-1614.
162. Lanzafame AA, Turnbull L, Amiramahdi F, Arthur JF, Huynh H, and Woodcock EA (2006) Inositol phospholipids localized to caveolae in rat heart are regulated by alpha1-adrenergic receptors and by ischemia-reperfusion. Am J Physiol Heart Circ Physiol 290:H2059-H2065.
163. Lee DK, Lança AJ, Cheng R, Nguyen T, Ji XD, Gobeil F Jr, Chemtob S, George SR, and O'Dowd BF (2004) Agonist-independent nuclear localization of the Apelin, angiotensin AT1, and bradykinin B2 receptors. J Biol Chem 279:7901-7908.
164. Lemire I, Ducharme A, Tardif JC, Poulin F, Jones LR, Allen BG, Hébert TE, and Rindt H (2001) Cardiac-directed overexpression of wild-type alpha1Badrenergic receptor induces dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 281:H931-H938.
165. Levin MC, Marullo S, Muntaner O, Andersson B, and Magnusson Y (2002) The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 277:30429-30435.
166. Levy D, Garrison RJ, Savage DD, Kannel WB, and Castelli WP (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322:1561-1566.
167. 1-AR-induced STAT3 activation and cardiac hypertrophy. Am J Physiol Heart Circ Physiol 301:H1941-H1951.
168. Liang Q, De Windt LJ, Witt SA, Kimball TR, Markham BE, and Molkentin JD (2001a) The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. J Biol Chem 276:30245-30253.
169. Liang Q, Wiese RJ, Bueno OF, Dai YS, Markham BE, and Molkentin JD (2001b) The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1-and 2-mediated phosphorylation of serine 105 in cardiomyocytes. Mol Cell Biol 21: 7460-7469.
170. Lin F, Owens WA, Chen S, Stevens ME, Kesteven S, Arthur JF, Woodcock EA, Feneley MP, and Graham RM (2001) Targeted alpha(1A)-adrenergic receptor overexpression induces enhanced cardiac contractility but not hypertrophy. Circ Res 89:343-350.
171. Lips DJ, Bueno OF, Wilkins BJ, Purcell NH, Kaiser RA, Lorenz JN, Voisin L, Saba-El-Leil MK, Meloche S, and Pouysségur J, et al. (2004) MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation 109: 1938-1941.
172. Litwin SE, Vatner DE, and Morgan JP (1995) Inotropic effects of alpha 1-adrenergic agonists in myocardium from rats with postinfarction heart failure. Am J Physiol 269:H1553-H1563.
173. Liu Y, Contreras M, Shen T, Randall WR, and Schneider MF (2009) Alpha-adrenergic signalling activates protein kinase D and causes nuclear efflux of the transcriptional repressor HDAC5 in cultured adult mouse soleus skeletal muscle fibres. J Physiol 587:1101-1115.
174. Lohse MJ, Engelhardt S, and Eschenhagen T (2003) What is the role of betaadrenergic signaling in heart failure? Circ Res 93:896-906.
175. Long CS, Ordahl CP, and Simpson PC (1989) Alpha 1-adrenergic receptor stimulation of sarcomeric actin isogene transcription in hypertrophy of cultured rat heart muscle cells. J Clin Invest 83:1078-1082.
176. Lopez I, Mak EC, Ding J, Hamm HE, and Lomasney JW (2001) A novel bifunctional phospholipase c that is regulated by Galpha 12 and stimulates the Ras/mitogenactivated protein kinase pathway. J Biol Chem 276:2758-2765.
177. López JE, Myagmar BE, Swigart PM, Montgomery MD, Haynam S, Bigos M, Rodrigo MC, and Simpson PC (2011) β-myosin heavy chain is induced by pressure overload in a minor subpopulation of smaller mouse cardiac myocytes. Circ Res 109:629-638.
178. Loubani M and Galiñanes M (2001) alpha1-Adrenoceptors during simulated ischemia and reoxygenation of the human myocardium: effect of the dose and time of administration. J Thorac Cardiovasc Surg 122:103-112.
179. Loubani M and Galiñanes M (2002) Pharmacological and ischemic preconditioning of the human myocardium: mitoK(ATP) channels are upstream and p38MAPK is downstream of PKC. BMC Physiol 2:10.
180. Lu D, Yang H, Shaw G, and Raizada MK (1998) Angiotensin II-induced nuclear targeting of the angiotensin type 1 (AT1) receptor in brain neurons. Endocrinology 139:365-375.
181. Lund-Johansen P and Omvik P (1991) Acute and chronic hemodynamic effects of drugs with different actions on adrenergic receptors: a comparison between alpha blockers and different types of beta blockers with and without vasodilating effect. Cardiovasc Drugs Ther 5:605-615.
182. 2+ signaling in cardiomyocytes. Acta Pharmacol Sin 28:968-974.
183. Lusk CP, Blobel G, and King MC (2007) Highway to the inner nuclear membrane: rules for the road. Nat Rev Mol Cell Biol 8:414-420.
184. MacGowan GA, Rager J, Shroff SG, and Mathier MA (2005) In vivo alpha-adrenergic responses and troponin I phosphorylation: anesthesia interactions. J Appl Physiol (1985) 98:1163-1170.
185. Mackenzie JF, Daly CJ, Pediani JD, and McGrath JC (2000) Quantitative imaging in live human cells reveals intracellular alpha(1)-adrenoceptor ligand-binding sites. J Pharmacol Exp Ther 294:434-443.
186. Mann DL, Kent RL, Parsons B, and Cooper G 4th (1992) Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 85:790-804.
187. Marino TA, Cassidy M, Marino DR, Carson NL, and Houser S (1991) Norepinephrineinduced cardiac hypertrophy of the cat heart. Anat Rec 229:505-510.
188. Markou T, Hadzopoulou-Cladaras M, and Lazou A (2004) Phenylephrine induces activation of CREB in adult rat cardiac myocytes through MSK1 and PKA signaling pathways. J Mol Cell Cardiol 37:1001-1011.
189. Marrache AM, Gobeil F Jr, Bernier SG, Stankova J, Rola-Pleszczynski M, Choufani S, Bkaily G, Bourdeau A, Sirois MG, and Vazquez-Tello A, et al. (2002) Proinflammatory gene induction by platelet-activating factor mediated via its cognate nuclear receptor. J Immunol 169:6474-6481.
190. McCloskey DT, Turnbull L, Swigart P, O'Connell TD, Simpson PC, and Baker AJ (2003) Abnormal myocardial contraction in alpha(1A)-and alpha(1B)-adrenoceptor double-knockout mice. J Mol Cell Cardiol 35:1207-1216.
191. McLean BG, Lee KS, Simpson PC, and Farrance IK (2003) Basal and alpha1-adrenergic-induced activity of minimal rat betaMHC promoters in cardiac myocytes requires multiple TEF-1 but not NFAT binding sites. J Mol Cell Cardiol 35: 461-471.
192. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, and Parker JD, et al.; VERITAS Investigators (2007) Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 298:2009-2019.
193. McWhinney CD, Hansen C, and Robishaw JD (2000) Alpha-1 adrenergic signaling in a cardiac murine atrial myocyte (HL-1) cell line. Mol Cell Biochem 214:111-119.
194. Meldrum DR, Cleveland JC Jr, Rowland RT, Banerjee A, Harken AH, and Meng X (1997) Early and delayed preconditioning: differential mechanisms and additive protection. Am J Physiol 273:H725-H733.
195. Melien O, Sandnes D, Johansen EJ, and Christoffersen T (2000) Effects of pertussis toxin on extracellular signal-regulated kinase activation in hepatocytes by hormones and receptor-independent agents: evidence suggesting a stimulatory role of G(i) proteins at a level distal to receptor coupling. J Cell Physiol 184:27-36.
196. Meng X, Brown JM, Ao L, Banerjee A, and Harken AH (1996a) Norepinephrine induces cardiac heat shock protein 70 and delayed cardioprotection in the rat through alpha 1 adrenoceptors. Cardiovasc Res 32:374-383.
197. Meng X, Cleveland JC Jr, Rowland RT, Mitchell MB, Brown JM, Banerjee A, and Harken AH (1996b) Norepinephrine-induced sustained myocardial adaptation to ischemia is dependent on alpha 1-adrenoceptors and protein synthesis. J Mol Cell Cardiol 28:2017-2025.
198. Meng X, Shames BD, Pulido EJ, Meldrum DR, Ao L, Joo KS, Harken AH, and Banerjee A (1999) Adrenergic induction of bimodal myocardial protection: signal transduction and cardiac gene reprogramming. Am J Physiol 276: R1525-R1533.
199. MERIT (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007.
200. Messerli FH (2000) Implications of discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Lancet 355:863-864.
201. Messerli FH (2001) Doxazosin and congestive heart failure. J Am Coll Cardiol 38: 1295-1296.
202. Methven L, Simpson PC, and McGrath JC (2009) Alpha1A/B-knockout mice explain the native alpha1D-adrenoceptor's role in vasoconstriction and show that its location is independent of the other alpha1-subtypes. Br J Pharmacol 158: 1663-1675.
203. Michel MC (2010) The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: alpha-blockers in the treatment of male voiding dysfunction-how do they work and why do they differ in tolerability? J Pharmacol Sci 112:151-157.
204. Michel MC, Hanft G, and Gross G (1994) Radioligand binding studies of alpha 1-adrenoceptor subtypes in rat heart. Br J Pharmacol 111:533-538.
205. Michel MC, Wieland T, and Tsujimoto G (2009) How reliable are G-protein-coupled receptor antibodies? Naunyn Schmiedebergs Arch Pharmacol 379:385-388.
206. Michelotti GA, Price DT, and Schwinn DA (2000) Alpha 1-adrenergic receptor regulation: basic science and clinical implications. Pharmacol Ther 88:281-309.
207. Milano CA, Dolber PC, Rockman HA, Bond RA, Venable ME, Allen LF, and Lefkowitz RJ (1994) Myocardial expression of a constitutively active alpha 1Badrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci USA 91:10109-10113.
208. Mitchell MB, Meng X, Ao L, Brown JM, Harken AH, and Banerjee A (1995) Preconditioning of isolated rat heart is mediated by protein kinase C. Circ Res 76: 73-81.
209. Modesti PA, Vanni S, Paniccia R, Bandinelli B, Bertolozzi I, Polidori G, Sani G, and Neri Serneri GG (1999) Characterization of endothelin-1 receptor subtypes in isolated human cardiomyocytes. J Cardiovasc Pharmacol 34:333-339.
210. Mohl MC, Iismaa SE, Xiao XH, Friedrich O, Wagner S, Nikolova-Krstevski V, Wu J, Yu ZY, Feneley M, and Fatkin D, et al. (2011) Regulation of murine cardiac contractility by activation of α(1A)-adrenergic receptor-operated Ca(2+) entry. Cardiovasc Res 91:310-319.
211. Morimoto T, Hasegawa K, Kaburagi S, Kakita T, Wada H, Yanazume T, and Sasayama S (2000) Phosphorylation of GATA-4 is involved in alpha 1-adrenergic agonist-responsive transcription of the endothelin-1 gene in cardiac myocytes. J Biol Chem 275:13721-13726.
212. Morris JB, Huynh H, Vasilevski O, and Woodcock EA (2006) Alpha1-adrenergic receptor signaling is localized to caveolae in neonatal rat cardiomyocytes. J Mol Cell Cardiol 41:17-25.
213. Morris JB, Pham TM, Kenney B, Sheppard KE, and Woodcock EA (2004) UTP transactivates epidermal growth factor receptors and promotes cardiomyocyte hypertrophy despite inhibiting transcription of the hypertrophic marker gene, atrial natriuretic peptide. J Biol Chem 279:8740-8746.
214. Mylona P and Cleland JG (1999) Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio. net Editorial Team. Eur J Heart Fail 1:197-200.
215. Naga Prasad SV, Nienaber J, and Rockman HA (2001) Beta-adrenergic axis and heart disease. Trends Genet 17:S44-S49.
216. 2+-and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest 117: 2431-2444.
217. Nemchenko A, Chiong M, Turer A, Lavandero S, and Hill JA (2011) Autophagy as a therapeutic target in cardiovascular disease. J Mol Cell Cardiol 51:584-593.
218. Nishida K and Otsu K (2008) Cell death in heart failure. Circ J 72 Suppl A:A17-21.
219. 2+ in activation of protein kinase C during ischemic preconditioning. Circulation 96:1257-1265.
220. Noguchi H, Muraoka R, Kigoshi S, and Muramatsu I (1995) Pharmacological characterization of alpha 1-adrenoceptor subtypes in rat heart: a binding study. Br J Pharmacol 114:1026-1030.
221. O'Connell TD, Ishizaka S, Nakamura A, Swigart PM, Rodrigo MC, Simpson GL, Cotecchia S, Rokosh DG, Grossman W, and Foster E, et al. (2003) The alpha(1A/C)-and alpha(1B)-adrenergic receptors are required for physiological cardiac hypertrophy in the double-knockout mouse. J Clin Invest 111:1783-1791.
222. O'Connell TD, Rokosh DG, and Simpson PC (2001) Cloning and characterization of the mouse alpha1C/A-adrenergic receptor gene and analysis of an alpha1C promoter in cardiac myocytes: role of an MCAT element that binds transcriptional enhancer factor-1 (TEF-1). Mol Pharmacol 59:1225-1234.
223. O'Connell TD, Swigart PM, Rodrigo MC, Ishizaka S, Joho S, Turnbull L, Tecott LH, Baker AJ, Foster E, and Grossman W, et al. (2006) Alpha1-adrenergic receptors prevent a maladaptive cardiac response to pressure overload. J Clin Invest 116:1005-1015.
224. 2+ changes in heterologous cell types and neurons. J Biol Chem 278: 28210-28219.
225. Obst OO, Rose H, and Kammermeier H (1996) Characterization of catecholamine uptake2 in isolated cardiac myocytes. Mol Cell Biochem 163-164:181-183.
226. 2+/calmodulin-dependent PK II (CaMKII) activation in rat ventricular myocytes. Proc Natl Acad Sci U S A 102:9400-9405.
227. 2+ channel. Circ Res 102:1378-1388.
228. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, and Shusterman NH; U.S. Carvedilol Heart Failure Study Group (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1355.
229. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, and Roecker EB, et al.; Carvedilol Prospective Randomized Cumulative Survival Study Group (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658.
230. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, and Staiger C, et al.; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group (2002) Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106:2194-2199.
231. 1A-adrenergic receptors regulate cardiac hypertrophy in vivo through interleukin-6 secretion. Mol Pharmacol 83:939-948.
232. Paradis P, Dali-Youcef N, Paradis FW, Thibault G, and Nemer M (2000) Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci USA 97:931-936.
233. Patel MB, Stewart JM, Loud AV, Anversa P, Wang J, Fiegel L, and Hintze TH (1991) Altered function and structure of the heart in dogs with chronic elevation in plasma norepinephrine. Circulation 84:2091-2100.
234. Pediani JD, Colston JF, Caldwell D, Milligan G, Daly CJ, and McGrath JC (2005) Beta-arrestin-dependent spontaneous alpha1a-adrenoceptor endocytosis causes intracellular transportation of alpha-blockers via recycling compartments. Mol Pharmacol 67:992-1004.
235. Piascik MT and Perez DM (2001) Alpha1-adrenergic receptors: new insights and directions. J Pharmacol Exp Ther 298:403-410.
236. Pickard BW, Hodsman AB, Fraher LJ, and Watson PH (2006) Type 1 parathyroid hormone receptor (PTH1R) nuclear trafficking: association of PTH1R with importin alpha1 and beta. Endocrinology 147:3326-3332.
237. Pickard BW, Hodsman AB, Fraher LJ, and Watson PH (2007) Type 1 parathyroid hormone receptor (PTH1R) nuclear trafficking: regulation of PTH1R nuclearcytoplasmic shuttling by importin-alpha/beta and chromosomal region maintenance 1/exportin 1. Endocrinology 148:2282-2289.
238. Piller LB, Davis BR, Cutler JA, Cushman WC, Wright JT Jr, Williamson JD, Leenen FH, Einhorn PT, Randall OS, and Golden JS, et al. The ALLHAT Collaborative Research Group (2002) Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone. Curr Control Trials Cardiovasc Med 3:10.
239. Pocock S, Wilhelmsen L, Dickstein K, Francis G, and Wittes J (2004) The data monitoring experience in the MOXCON trial. Eur Heart J 25:1974-1978.
240. Pönicke K, Vogelsang M, Heinroth M, Becker K, Zolk O, Böhm M, Zerkowski HR, and Brodde OE (1998) Endothelin receptors in the failing and nonfailing human heart. Circulation 97:744-751.
241. Poole-Wilson PA, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Metra M, J Remme W, Swedberg K, and Torp-Pedersen C (2002) Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. Eur J Heart Fail 4:321-329.
242. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, and Remme WJ, et al.; Carvedilol Or Metoprolol European Trial Investigators (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362:7-13.
243. Post GR, Swiderski C, Waldrop BA, Salty L, Glembotski CC, Wolthuis RM, and Mochizuki N (2002) Guanine nucleotide exchange factor-like factor (Rlf) induces gene expression and potentiates α1-adrenergic receptor-induced transcriptional responses in neonatal rat ventricular myocytes. J Biol Chem 277: 15286-15292.
244. Pu WT, Ma Q, and Izumo S (2003) NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro. Circ Res 92:725-731.
245. Ravens U, Wang XL, and Wettwer E (1989) Alpha adrenoceptor stimulation reduces outward currents in rat ventricular myocytes. J Pharmacol Exp Ther 250:364-370.
246. Re M, Pampillo M, Savard M, Dubuc C, McArdle CA, Millar RP, Conn PM, Gobeil F Jr, Bhattacharya M, and Babwah AV (2010) The human gonadotropin releasing hormone type I receptor is a functional intracellular GPCR expressed on the nuclear membrane. PLoS ONE 5:e11489.
247. Rockman HA, Choi DJ, Rahman NU, Akhter SA, Lefkowitz RJ, and Koch WJ (1996) Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. Proc Natl Acad Sci USA 93:9954-9959.
248. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, and Ford ES, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2011) Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 123:e18-e209.
249. Rohde S, Sabri A, Kamasamudran R, and Steinberg SF (2000) The alpha(1)-adrenoceptor subtype-and protein kinase C isoform-dependence of Norepinephrine's actions in cardiomyocytes. J Mol Cell Cardiol 32:1193-1209.
250. Rokosh DG, Bailey BA, Stewart AF, Karns LR, Long CS, and Simpson PC (1994) Distribution of alpha 1C-adrenergic receptor mRNA in adult rat tissues by RNase protection assay and comparison with alpha 1B and alpha 1D. Biochem Biophys Res Commun 200:1177-1184.
251. Rokosh DG and Simpson PC (2002) Knockout of the alpha 1A/C-adrenergic receptor subtype: the alpha 1A/C is expressed in resistance arteries and is required to maintain arterial blood pressure. Proc Natl Acad Sci USA 99:9474-9479.
252. Rokosh DG, Stewart AF, Chang KC, Bailey BA, Karliner JS, Camacho SA, Long CS, and Simpson PC (1996) Alpha1-adrenergic receptor subtype mRNAs are differentially regulated by alpha1-adrenergic and other hypertrophic stimuli in cardiac myocytes in culture and in vivo. Repression of alpha1B and alpha1D but induction of alpha1C. J Biol Chem 271:5839-5843.
253. Rorabaugh BR, Ross SA, Gaivin RJ, Papay RS, McCune DF, Simpson PC, and Perez DM (2005) alpha1A-but not alpha1B-adrenergic receptors precondition the ischemic heart by a staurosporine-sensitive, chelerythrine-insensitive mechanism. Cardiovasc Res 65:436-445.
254. Ross SA, Rorabaugh BR, Chalothorn D, Yun J, Gonzalez-Cabrera PJ, McCune DF, Piascik MT, and Perez DM (2003) The alpha(1B)-adrenergic receptor decreases the inotropic response in the mouse Langendorff heart model. Cardiovasc Res 60: 598-607.
255. Sakata Y, Hoit BD, Liggett SB, Walsh RA, and Dorn GW 2nd (1998) Decompensation of pressure-overload hypertrophy in G alpha q-overexpressing mice. Circulation 97: 1488-1495.
256. Salazar NC, Chen J, and Rockman HA (2007) Cardiac GPCRs: GPCR signaling in healthy and failing hearts. Biochim Biophys Acta 1768:1006-1018.
257. Sato R and Koumi S (1995) Modulation of the inwardly rectifying K+ channel in isolated human atrial myocytes by alpha 1-adrenergic stimulation. J Membr Biol 148:185-191.
258. Schomig E, Lazar A, and Grundemann D (2006) Extraneuronal monoamine transporter and organic cation transporters 1 and 2: A review of transport efficiency. Handb Exp Pharmacol 175:151-180.
259. Schwinn DA and Roehrborn CG (2008) Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol 15:193-199.
260. Sica DA (2005) Alpha1-adrenergic blockers: current usage considerations. J Clin Hypertens (Greenwich) 7:757-762.
261. Simpson P (1983) Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response. J Clin Invest 72:732-738.
262. Simpson P (1985) Stimulation of hypertrophy of cultured neonatal rat heart cells through an alpha 1-adrenergic receptor and induction of beating through an alpha 1-and beta 1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating. Circ Res 56:884-894.
263. Simpson P, McGrath A, and Savion S (1982) Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines. Circ Res 51: 787-801.
264. Simpson PC (1988) Comments on "Load regulation of the properties of adult feline cardiocytes: the role of substrate adhesion. Circ Res 1986;58:692-705.
265. Simpson PC (2006) Lessons from Knockouts: the alpha-1-ARs, in The Adrenergic Receptors in the 21st Century (Perez DM, ed) pp 207-240, Humana Press, Totowa, NJ.
266. Simpson PC (2011) Where are the new drugs to treat heart failure? Introduction to the special issue on "key signaling molecules in hypertrophy and heart failure". J Mol Cell Cardiol 51:435-437.
267. Simpson PC, Long CS, Waspe LE, Henrich CJ, and Ordahl CP (1989) Transcription of early developmental isogenes in cardiac myocyte hypertrophy. J Mol Cell Cardiol 21 (Suppl 5):79-89.
268. Sjaastad I, Schiander I, Sjetnan A, Qvigstad E, Bøkenes J, Sandnes D, Osnes JB, Sejersted OM, and Skomedal T (2003) Increased contribution of alpha 1-vs. betaadrenoceptor-mediated inotropic response in rats with congestive heart failure. Acta Physiol Scand 177:449-458.
269. Skomedal T, Borthne K, Aass H, Geiran O, and Osnes JB (1997) Comparison between alpha-1 adrenoceptor-mediated and beta adrenoceptor-mediated inotropic components elicited by norepinephrine in failing human ventricular muscle. J Pharmacol Exp Ther 280:721-729.
270. Snabaitis AK, Muntendorf A, Wieland T, and Avkiran M (2005) Regulation of the extracellular signal-regulated kinase pathway in adult myocardium: differential roles of G(q/11), Gi and G(12/13) proteins in signalling by alpha1-adrenergic, endothelin-1 and thrombin-sensitive protease-activated receptors. Cell Signal 17: 655-664.
271. SoRelle R (2000) National Heart, Lung, and Blood Institute halts part of antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation 101:E9025.
272. Staehelin M, Simons P, Jaeggi K, and Wigger N (1983) CGP-12177. A hydrophilic beta-adrenergic receptor radioligand reveals high affinity binding of agonists to intact cells. J Biol Chem 258:3496-3502.
273. Stafford RS, Furberg CD, Finkelstein SN, Cockburn IM, Alehegn T, and Ma J (2004) Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002. JAMA 291:54-62.
274. Stanasila L, Abuin L, Dey J, and Cotecchia S (2008) Different internalization properties of the alpha1a-and alpha1b-adrenergic receptor subtypes: the potential role of receptor interaction with beta-arrestins and AP50. Mol Pharmacol 74: 562-573.
275. Starksen NF, Simpson PC, Bishopric N, Coughlin SR, Lee WM, Escobedo JA, and Williams LT (1986) Cardiac myocyte hypertrophy is associated with c-myc protooncogene expression. Proc Natl Acad Sci USA 83:8348-8350.
276. Steinberg SF, Drugge ED, Bilezikian JP, and Robinson RB (1985) Acquisition by innervated cardiac myocytes of a pertussis toxin-specific regulatory protein linked to the alpha 1-receptor. Science 230:186-188.
277. Steinfath M, Chen YY, Lavický J, Magnussen O, Nose M, Rosswag S, Schmitz W, and Scholz H (1992a) Cardiac alpha 1-adrenoceptor densities in different mammalian species. Br J Pharmacol 107:185-188.
278. Steinfath M, Danielsen W, von der Leyen H, Mende U, Meyer W, Neumann J, Nose M, Reich T, Schmitz W, and Scholz H, et al. (1992b) Reduced alpha 1-and beta 2-adrenoceptor-mediated positive inotropic effects in human end-stage heart failure. Br J Pharmacol 105:463-469.
279. Stewart AF, Rokosh DG, Bailey BA, Karns LR, Chang KC, Long CS, Kariya K, and Simpson PC (1994) Cloning of the rat alpha 1C-adrenergic receptor from cardiac myocytes. alpha 1C, alpha 1B, and alpha 1D mRNAs are present in cardiac myocytes but not in cardiac fibroblasts. Circ Res 75:796-802.
280. Stewart JM, Patel MB, Wang J, Ochoa M, Gewitz M, Loud AV, Anversa P, and Hintze TH (1992) Chronic elevation of norepinephrine in conscious dogs produces hypertrophy with no loss of LV reserve. Am J Physiol 262:H331-H339.
281. Swedberg K, Bristow MR, Cohn JN, Dargie H, Straub M, Wiltse C, and Wright TJ; Moxonidine Safety and Efficacy (MOXSE) Investigators (2002) Effects of sustainedrelease moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 105:1797-1803.
282. Tadevosyan A, Maguy A, Villeneuve LR, Babin J, Bonnefoy A, Allen BG, and Nattel S (2010) Nuclear-delimited angiotensin receptor-mediated signaling regulates cardiomyocyte gene expression. J Biol Chem 285:22338-22349.
283. Tadevosyan A, Vaniotis G, Allen BG, Hébert TE, and Nattel S (2012) G proteincoupled receptor signalling in the cardiac nuclear membrane: evidence and possible roles in physiological and pathophysiological function. J Physiol 590:1313-1330.
284. Tanoue A, Nasa Y, Koshimizu T, Shinoura H, Oshikawa S, Kawai T, Sunada S, Takeo S, and Tsujimoto G (2002) The alpha(1D)-adrenergic receptor directly regulates arterial blood pressure via vasoconstriction. J Clin Invest 109:765-775.
285. Teerlink JR and Massie BM (1999) Beta-adrenergic blocker mortality trials in congestive heart failure. Am J Cardiol 84 (9A):94R-102R.
286. Tejero-Taldo MI, Gursoy E, Zhao TC, and Kukreja RC (2002) Alpha-adrenergic receptor stimulation produces late preconditioning through inducible nitric oxide synthase in mouse heart. J Mol Cell Cardiol 34:185-195.
287. Terzic A, Pucéat M, Clément O, Scamps F, and Vassort G (1992) Alpha 1-adrenergic effects on intracellular pH and calcium and on myofilaments in single rat cardiac cells. J Physiol 447:275-292.
288. Tohse N, Nakaya H, Hattori Y, Endou M, and Kanno M (1990) Inhibitory effect mediated by alpha 1-adrenoceptors on transient outward current in isolated rat ventricular cells. Pflugers Arch 415:575-581.
289. Tohse N, Nakaya H, and Kanno M (1992) Alpha 1-adrenoceptor stimulation enhances the delayed rectifier K+ current of guinea pig ventricular cells through the activation of protein kinase C. Circ Res 71:1441-1446.
290. Tosaki A, Behjet NS, Engelman DT, Engelman RM, and Das DK (1995) Alpha-1 adrenergic receptor agonist-induced preconditioning in isolated working rat hearts. J Pharmacol Exp Ther 273:689-694.
291. Tsuchida A, Liu Y, Liu GS, Cohen MV, and Downey JM (1994) alpha 1-adrenergic agonists precondition rabbit ischemic myocardium independent of adenosine by direct activation of protein kinase C. Circ Res 75:576-585.
292. Turnbull L, McCloskey DT, O'Connell TD, Simpson PC, and Baker AJ (2003) Alpha 1-adrenergic receptor responses in alpha 1AB-AR knockout mouse hearts suggest the presence of alpha 1D-AR. Am J Physiol Heart Circ Physiol 284:H1104-H1109.
293. Vago T, Bevilacqua M, Norbiato G, Baldi G, Chebat E, Bertora P, Baroldi G, and Accinni R (1989) Identification of alpha 1-adrenergic receptors on sarcolemma from normal subjects and patients with idiopathic dilated cardiomyopathy: characteristics and linkage to GTP-binding protein. Circ Res 64:474-481.
294. Valks DM, Cook SA, Pham FH, Morrison PR, Clerk A, and Sugden PH (2002) Phenylephrine promotes phosphorylation of Bad in cardiac myocytes through the extracellular signal-regulated kinases 1/2 and protein kinase A. J Mol Cell Cardiol 34:749-763.
295. VanTassell BW, Rondina MT, Huggins F, Gilbert EM, and Munger MA (2008) Carvedilol increases blood pressure response to phenylephrine infusion in heart failure subjects with systolic dysfunction: evidence of improved vascular alpha1-adrenoreceptor signal transduction. Am Heart J 156:315-321.
296. Vaniotis G, Del Duca D, Trieu P, Rohlicek CV, Hébert TE, and Allen BG (2011) Nuclear β-adrenergic receptors modulate gene expression in adult rat heart. Cell Signal 23:89-98.
297. Vaughan ED Jr (2003) Medical management of benign prostatic hyperplasia-are two drugs better than one? N Engl J Med 349:2449-2451.
298. Vecchione C, Fratta L, Rizzoni D, Notte A, Poulet R, Porteri E, Frati G, Guelfi D, Trimarco V, and Mulvany MJ, et al. (2002) Cardiovascular influences of alpha1badrenergic receptor defect in mice. Circulation 105:1700-1707.
299. Vega RB, Harrison BC, Meadows E, Roberts CR, Papst PJ, Olson EN, and McKinsey TA (2004) Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol 24:8374-8385.
300. 1-adrenoceptor induced hypertrophy in neonatal rat cardiomyocytes. J Mol Cell Cardiol 53:165-175.
301. Vinge LE, Andressen KW, Attramadal T, Andersen GO, Ahmed MS, Peppel K, Koch WJ, Freedman NJ, Levy FO, and Skomedal T, et al. (2007) Substrate specificities of g protein-coupled receptor kinase-2 and-3 at cardiac myocyte receptors provide basis for distinct roles in regulation of myocardial function. Mol Pharmacol 72: 582-591.
302. Vinge LE, Øie E, Andersson Y, Grøgaard HK, Andersen G, and Attramadal H (2001) Myocardial distribution and regulation of GRK and beta-arrestin isoforms in congestive heart failure in rats. Am J Physiol Heart Circ Physiol 281:H2490-H2499.
303. Volz A, Piper HM, Siegmund B, and Schwartz P (1991) Longevity of adult ventricular rat heart muscle cells in serum-free primary culture. J Mol Cell Cardiol 23:161-173.
304. Wang BH, Du XJ, Autelitano DJ, Milano CA, and Woodcock EA (2000) Adverse effects of constitutively active alpha(1B)-adrenergic receptors after pressure overload in mouse hearts. Am J Physiol Heart Circ Physiol 279:H1079-H1086.
305. Wang GY, McCloskey DT, Turcato S, Swigart PM, Simpson PC, and Baker AJ (2006) Contrasting inotropic responses to alpha1-adrenergic receptor stimulation in left versus right ventricular myocardium. Am J Physiol Heart Circ Physiol 291:H2013-H2017.
306. Wang GY, Yeh CC, Jensen BC, Mann MJ, Simpson PC, and Baker AJ (2010) Heart failure switches the RV alpha1-adrenergic inotropic response from negative to positive. Am J Physiol Heart Circ Physiol 298:H913-H920.
307. Wang H, Yang B, Zhang Y, Han H, Wang J, Shi H, and Wang Z (2001) Different subtypes of alpha1-adrenoceptor modulate different K+ currents via different signaling pathways in canine ventricular myocytes. J Biol Chem 276:40811-40816.
308. Wang XL, Wettwer E, Gross G, and Ravens U (1991) Reduction of cardiac outward currents by alpha-1 adrenoceptor stimulation: a subtype-specific effect? J Pharmacol Exp Ther 259:783-788.
309. Waspe LE, Ordahl CP, and Simpson PC (1990) The cardiac beta-myosin heavy chain isogene is induced selectively in alpha 1-adrenergic receptor-stimulated hypertrophy of cultured rat heart myocytes. J Clin Invest 85:1206-1214.
310. Wencker D, Chandra M, Nguyen K, Miao W, Garantziotis S, Factor SM, Shirani J, Armstrong RC, and Kitsis RN (2003) A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 111:1497-1504.
311. Whelan RS, Kaplinskiy V, and Kitsis RN (2010) Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol 72:19-44.
312. Wollert KC and Drexler H (2002) Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol as the sun and center of the beta-blocker world? Circulation 106:2164-2166.
313. 2+ current in guinea-pig ventricular myocytes. Pflugers Arch 437:335-344.
314. Wright CD, Chen Q, Baye NL, Huang Y, Healy CL, Kasinathan S, and O'Connell TD (2008) Nuclear alpha1-adrenergic receptors signal activated ERK localization to caveolae in adult cardiac myocytes. Circ Res 103:992-1000.
315. Wright CD, Wu SC, Dahl EF, Sazama AJ, and O'Connell TD (2012) Nuclear localization drives α1-adrenergic receptor oligomerization and signaling in cardiac myocytes. Cell Signal 24:794-802.
316. Xiao L, Pimental DR, Amin JK, Singh K, Sawyer DB, and Colucci WS (2001) MEK1/ 2-ERK1/2 mediates alpha1-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. J Mol Cell Cardiol 33:779-787.
317. Xiao RP, Zhu W, Zheng M, Chakir K, Bond R, Lakatta EG, and Cheng H (2004) Subtype-specific beta-adrenoceptor signaling pathways in the heart and their potential clinical implications. Trends Pharmacol Sci 25:358-365.
318. Yang LL, Gros R, Kabir MG, Sadi A, Gotlieb AI, Husain M, and Stewart DJ (2004) Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice. Circulation 109:255-261.
319. Yang M, Reese J, Cotecchia S, and Michel MC (1998) Murine alpha1-adrenoceptor subtypes. I. Radioligand binding studies. J Pharmacol Exp Ther 286:841-847.
320. Zakir RM, Folefack A, Saric M, and Berkowitz RL (2009) The use of midodrine in patients with advanced heart failure. Congest Heart Fail 15:108-111.
321. Zhang L, Malik S, Kelley GG, Kapiloff MS, and Smrcka AV (2011) Phospholipase C epsilon scaffolds to muscle-specific A kinase anchoring protein (mAKAPbeta) and integrates multiple hypertrophic stimuli in cardiac myocytes. J Biol Chem 286: 23012-23021.
322. Zhang L, Malik S, Pang J, Wang H, Park KM, Yule DI, Blaxall BC, and Smrcka AV (2013) Phospholipase Cε hydrolyzes perinuclear phosphatidylinositol 4-phosphate to regulate cardiac hypertrophy. Cell 153:216-227.
323. 2+ current in rat ventricular myocytes. J Mol Cell Cardiol 30:1955-1965.
324. Zhao X, Park J, Ho D, Gao S, Yan L, Ge H, Iismaa S, Lin L, Tian B, and Vatner DE, et al. (2012) Cardiomyocyte overexpression of the α1A-adrenergic receptor in the rat phenocopies second but not first window preconditioning. Am J Physiol Heart Circ Physiol 302:H1614-H1624.
325. Zhu H, McElwee-Witmer S, Perrone M, Clark KL, and Zilberstein A (2000) Phenylephrine protects neonatal rat cardiomyocytes from hypoxia and serum deprivationinduced apoptosis. Cell Death Differ 7:773-784.
326. Zuscik MJ, Chalothorn D, Hellard D, Deighan C, McGee A, Daly CJ, Waugh DJ, Ross SA, Gaivin RJ, and Morehead AJ, et al. (2001) Hypotension, autonomic failure, and cardiac hypertrophy in transgenic mice overexpressing the alpha 1B-adrenergic receptor. J Biol Chem 276:13738-13743.
327. Zwart R, Verhaagh S, Buitelaar M, Popp-Snijders C, and Barlow DP (2001) Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice. Mol Cell Biol 21:4188-4196.